Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood and stool test slash gastrointestinal cancer deaths?

NCT ID NCT07712107

Diagnosis Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This large study is testing whether a combined screening approach—using a blood test for DNA markers plus stool tests for hidden blood and inflammation—can catch gastrointestinal cancers earlier and save lives. Researchers will randomly assign 10,000 adults aged 45–74 to either receive this screening or follow usual care, then track cancer rates and deaths over five years. The goal is to see if this multi-target strategy works better than current routine surveillance at reducing deaths from these cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multi-target blood methylation test, fecal FIT, and fecal calprotectin
What this could lead to
If successful, this screening approach could significantly reduce deaths from gastrointestinal cancers by catching them earlier and more accurately than current methods.
What could go wrong
The test may produce false positives or negatives, and its effectiveness depends on large-scale, long-term follow-up. Results will take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must be between 45 and 74 years of age at the time of enrollment; * Participants must agree to be randomly assigned to different screening and follow-up strategies; * Participants must agree to undergo a five-year follow-up in accordance with the protocol; * Participants must be willing to participate and sign an informed consent form. Exclusion Criteria: * Underwent upper gastrointestinal endoscopy screening within the past year; * History of any type of malignant tumor; * Concurrent severe medical conditions that reduce the benefits of screening, such as severe pulmonary disease, kidney disease, liver disease, cardiovascular and cerebrovascular diseases, and hematological disorders; * Other situations where a physician determines that endoscopic screening poses excessive risk (e.g., hemodynamic instability) or offers no benefit (e.g., short life expectancy); * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm Digestive System Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gaoyao District People's Hospital, Zhaoqing City, Guangdong Province

    RECRUITING

    Zhaoqing, Guangdong, China

  • The 960th Hospital of the Joint Support Force of the People's Liberation Army of China

    RECRUITING

    Jinan, China

  • Wuwei Cancer Hospital of Gansu Province

    RECRUITING

    Wuwei, China

  • Wuxi People's Hospital

    RECRUITING

    Wuxi, China

  • Yanting County Tumor Hospital

    RECRUITING

    Mianyang, China

  • Zhaoqing First People's Hospital, Guangdong Province

    RECRUITING

    Zhaoqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.